PBA
ENTA icon

Paradigm Biocapital Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-148,216
Closed -$7.01M – 30
2022
Q2 		$7.01M Buy
+148,216
New +$8.04M 1.4% 18
2022
Q1 		– Sell
-75,507
Closed -$5.65M – 27
2021
Q4 		$5.65M Buy
+75,507
New +$5.93M 1.61% 20

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Paradigm Biocapital Advisors's ENTA Position: Q3 2022 in Review

Paradigm Biocapital Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2022, closing a stake of 148,216 shares — an estimated $7.01M sold.

Paradigm Biocapital Advisors first reported a position in ENTA in Q4 2021 and held it in 2 quarters. The position peaked at $7.01M in Q2 2022. 159 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

  • Paradigm Biocapital Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 148,216 Enanta Pharmaceuticals shares in Q3 2022, an estimated $7.01M.
  • Paradigm Biocapital Advisors first reported a position in Enanta Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Enanta Pharmaceuticals position peaked at $7.01M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.